 Shares of Ionis Pharmaceuticals Inc. IONS, 5.11 fell 7.9 in premarket trading on Monday after the company and Pfizer Inc. PFE, 1.80 said they discontinued a program testing an experimental treatment for cardiovascular risk reduction and severe hypertriglyceridemia. The companies said that although the drug, vupanorsen, met the primary endpoint in a Phase 2b study, there was concern about its viability as a treatment for those indications. 